ATLANTA, July 15, 2021 /PRNewswire/ -- CryoLife, Inc.
(NYSE: CRY), a leading cardiac and vascular surgery company focused
on aortic disease, announced today that second quarter 2021
financial results will be released on Thursday, July 29, 2021 after the market
closes. On that day, the Company will hold a teleconference
call and live webcast at 4:30 p.m. ET
to discuss the results, followed by a question and answer session
hosted by Pat Mackin, Chairman,
President and Chief Executive Officer of CryoLife, Inc.
To listen to the live teleconference, please dial 201-689-8261 a
few minutes prior to 4:30 p.m.
ET. A replay of the teleconference will be available
July 29 through August 5, 2021 and
can be accessed by calling (toll free) 877-660-6853 or
201-612-7415. The conference number for the replay is
13721548.
The live webcast and replay can be accessed in the Investor
Relations section of the CryoLife website at www.cryolife.com and
selecting Webcasts & Presentations. In addition, a copy
of the earnings press release, which will contain financial and
statistical information for the completed quarter and full year,
can be accessed in the Investor Relations section of the CryoLife
website.
About CryoLife, Inc.
Headquartered in suburban
Atlanta, Georgia, CryoLife is a
leader in the manufacturing, processing, and distribution of
medical devices and implantable tissues used in cardiac and
vascular surgical procedures focused on aortic repair.
CryoLife markets and sells products in more than 100 countries
worldwide. For additional information about CryoLife, visit
our website, www.cryolife.com.
Contacts:
CryoLife
D. Ashley
Lee
Executive Vice
President, Chief Financial Officer
and Chief Operating Officer
Phone: 770-419-3355
|
|
Gilmartin Group
LLC
Brian Johnston / Lynn
Lewis
Phone:
631-807-1986
investors@cryolife.com
|
View original content to download
multimedia:https://www.prnewswire.com/news-releases/cryolife-announces-release-date-and-teleconference-call-details-for-second-quarter-2021-financial-results-301335173.html
SOURCE CryoLife, Inc.